MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia

  1. Wei, Y.
  2. Zheng, H.
  3. Lockyer, P.P.
  4. Darbaniyan, F.
  5. Li, Z.
  6. Kanagal-Shamanna, R.
  7. Soltysiak, K.A.
  8. Yang, H.
  9. Ganan-Gomez, I.
  10. Montalban-Bravo, G.
  11. Chien, K.S.
  12. Do, K.-A.
  13. Daver, N.
  14. Garcia-Manero, G.
Aldizkaria:
Leukemia and Lymphoma

ISSN: 1029-2403 1042-8194

Argitalpen urtea: 2022

Alea: 63

Zenbakia: 13

Orrialdeak: 3154-3164

Mota: Artikulua

DOI: 10.1080/10428194.2022.2116932 GOOGLE SCHOLAR

Garapen Iraunkorreko Helburuak